Global Legionellosis Market Forecast, Trend Analysis, and Competition Tracking
Global Legionellosis Market – Industry Trends and Forecast to 2029
legionellosis market was valued at USD 1.2293 billion in 2021 and is expected to reach USD 2.36 billion by 2029, registering a CAGR of 8.50% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
In recent years, the legionellosis market is anticipated to grow rapidly during the forecast period. According to the Centers for Disease Control and Prevention (CDC), there were 6,238 cases of legionnaires disease in the United States in 2017. While this is a modest incidence rate, it represents a 13.6 percent increase in the number of cases when compared to 2016 predictions. Although legionellosis disease is not contagious, it can be spread by contaminated water droplets and mist. Legionellosis disease is an infrequent and sporadic respiratory infection in the EU countries, similar to the United States, with low notification rates.
Global Legionellosis Market Scope
Type
· Pneumonic
· Non-Pneumonic
Treatment
· Medication
· Antibiotics
· Sooner Therapy
Diagnosis
· Blood and Urine Tests
· Chest X-ray
· Sputum and Lung Tissue
Dosage form
· Tablets
· Capsules
· Injections
Route of Administration
· Oral
· Parenteral
End-Users
· Specialty Clinics
· Homecare
Distribution Channel
· Hospital Pharmacy
· Retail Pharmacy
· Online Pharmacy
Get the sample copy of Report here: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-legionellosis-market
Legionellosis Market Regional Analysis/Insights
The countries covered in the Legionellosis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Competitive Landscape and Legionellosis Market Share Analysis
· F. Hoffmann-La Roche Ltd. (Switzerland)
· Mylan N.V. (US)
· Teva Pharmaceutical Industries Ltd. (Ireland)
· Sanofi (France)
· Pfizer Inc. (US)
· GlaxoSmithKline plc (UK)
· Novartis AG (Switzerland)
· Bayer AG (Germany)
· Eli Lilly and Company (US)
· Merck & Co., Inc. (US)
· Allergan (Ireland)
· AstraZeneca (UK)
· AbbVie Inc. (US)
· Johnson & Johnson Private Limited (US)
· Cipla Inc. (US)
· Abbott (US)
· Merck KGaA (Germany)
· Sun Pharmaceutical Industries Ltd. (India)
· Aurobindo Pharma (India)
· Lupin (India)
· Hikma Pharmaceuticals PLC (UK)
· Fresenius Kabi AG (Germany)
· Almirall, S.A (Spain)
· Baxter (US)
Get Full Access of Report@ https://www.databridgemarketresearch.com/reports/global-legionellosis-market
MAJOR TOC OF THE REPORT
Ø INTRODUCTION
Ø MARKET SEGMENTATION
Ø EXECUTIVE SUMMARY
Ø PREMIUM INSIGHTS
Ø MARKET OVERVIEW
Ø QUESTIONNAIRE
RELATED REPORTS
Get TOC Details: https://www.databridgemarketresearch.com/toc/?dbmr=global-legionellosis-market
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Sopan.gedam@databridgemarketresearch.com
Browse Related Reports@
